Golph3: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Citation bot (talk | contribs)
m Removed parameters. | You can use this bot yourself. Report bugs here. | User-activated.
Cewbot (talk | contribs)
m Normalize {{Multiple issues}}: Remove {{Multiple issues}} for only 1 maintenance template(s): Underlinked
Line 1: Line 1:
{{multiple issues|
{{Underlinked|date=May 2014}}
{{Underlinked|date=May 2014}}
{{Orphan|date=May 2014}}
{{Orphan|date=May 2014}}
}}


'''Golgi phosphoprotein 3''' ('''GOLPH3''') is a human protein encoded by GOLPH3 gene. It is a peripheral membrane protein of the Golgi that probably has a regulatory role in Golgi trafficking.
'''Golgi phosphoprotein 3''' ('''GOLPH3''') is a human protein encoded by GOLPH3 gene. It is a peripheral membrane protein of the Golgi that probably has a regulatory role in Golgi trafficking.

Revision as of 17:49, 31 May 2020

Golgi phosphoprotein 3 (GOLPH3) is a human protein encoded by GOLPH3 gene. It is a peripheral membrane protein of the Golgi that probably has a regulatory role in Golgi trafficking. [1]

Clinical significance

Golph 3 expression is associated with poor prognosis of various cancers of gastrointestinal tract, such as gastric and esophageal squamous cell carcinoma.[2][3] Higher expression of GOLPH3 is reported to be associated with greater sensitivity of colorectal cancer to Fluorouracil therapy.[4]

Notes and references

  1. ^ "Entrez Gene: GOLPH3 golgi phosphoprotein 3".
  2. ^ Wang JH (2013). "High Expression of GOLPH3 in Esophageal Squamous Cell Carcinoma Correlates with Poor Prognosis". PLOS ONE. 7 (10): e45622. Bibcode:2012PLoSO...745622W. doi:10.1371/journal.pone.0045622. PMC 3462781. PMID 23056210.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  3. ^ Hu BS (Feb 2013). "Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer". Tumour Biol. 34 (1): 515–20. doi:10.1007/s13277-012-0576-z. PMID 23132295.
  4. ^ Wang Z (Jan 2014). "GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy". J. Transl. Med. 12 (1): 15. doi:10.1186/1479-5876-12-15. PMC 4029222. PMID 24444035.{{cite journal}}: CS1 maint: unflagged free DOI (link)